Drug Discovery World
APRIL 24, 2024
Evotec will identify best-in-class small molecules targeting a key fibrotic pathway with strong genetic support identified by Variant Bio and progress the programme towards the selection of a clinical development candidate(s) using its R&D platform.
Drug Discovery World
OCTOBER 25, 2023
iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumour survival pathways, has published new research data in the peer-reviewed journal Cancer Research, that supports a strategy of combining autotaxin inhibitor IOA-289 with TGF-Ī² pathway inhibitor IOA-359.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
MARCH 26, 2024
DDWās Megan Thomas caught up with Oliver Rausch, Chief Scientific Officer at Storm Therapeutics, following the ESMO Targeted Anticancer Therapies Congress 2024, a global meeting focusing on promising new anticancer targets and agents, focusing on those in early phase clinical development. MT: Whatās next for STORMās research?
Drug Discovery World
JANUARY 3, 2023
Merck KGaA will be solely responsible for in vitro and in vivo characterisation, other preclinical work, and all clinical development and potential commercialisation activities relating to any resulting product candidates. . Mersana will receive an upfront payment of $30 million.
Drug Discovery World
JUNE 6, 2023
In preclinical studies conducted by the company, BEN-34712 was neuroprotective in a patient-derived, disease-relevant in vitro motor neuron/iAstrocyte co-culture model, demonstrating significant efficacy in both sporadic and familial subtypes of ALS.
Drug Discovery World
JULY 3, 2023
Key updates The findings presented by Dr Christian Klein, Head of Oncology Programs and Department Head of Cancer Immunotherapy Discovery, Roche Innovation Center Zurich, Roche Pharma Research & Early Development, pRED, bear major implications for the development of the next-generation of IL-2 therapies.
The Pharma Data
JANUARY 6, 2021
SK Chemicals has shared their expertise in these diseases and validated the predicted targets and compounds through in vitro and in vivo studies. Further research on and development of the compound is ongoing with the objective of completing preclinical studies. About Standigm. Standigm is an AI-driven drug discovery company.
Expert insights. Personalized for you.
52 
Let's personalize your content